Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.2.787

Lack of Association between Using Aspirin and Development of Non-Hodgkins Lymphoma: A Meta-analysis  

Cheraghi, Maria (Social Determinants of Heath Research Center, School of Public Heath, Ahvaz Jundishapur University of Medical Sciences)
Amoori, Neda (Abadan School of Medical Sciences)
Fallahzadeh, Hosein (Department of Biostatic and Epidemiology, Shahid Sadoughi University of Medical Sciences)
Rahmani, Hossein (Department of Toxicology, Shahreza Branch, Islamic Azad University, Shahreza, and Medical Research Center, Jundishapur Health Development Co.)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.2, 2015 , pp. 787-792 More about this Journal
Abstract
Background: Non-Hodgkins lymphoma (NHL) is a heterogeneous group of malignancies, originating in the lymphatic organs, whose incidence is increasing in developed as well as developing countries. Epidemiological evidence suggests that aspirin may reduce the incidence and mortality of several cancers. The main objective of this study was to evaluate the potential relationship between using aspirin and development of NHL with a meta-analysis. Materials and Methods: A total of 7 studies were included. Outcome was calculated and reported as odds ratios (ORs). Heterogeneity was assessed with Cochrane Q and $I^2$ statistics. Dissemination bias was evaluated by funnel plot visualization and trim-and-fill analysis. Results: Our analysis showed OR of developing NHL overall of 1(95% CI: 0.87-1.16, p=0.9), and in females this was 0.81 (95%CI: 0.72-.92, p=0.001) and in males 1.01 (95%CI: 0.82-1.26, p=0.86). The odds ratio (OR) of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was 0.85 (95%CI: 0.75-0.97, p=0.02), The ORs of follicular lymphoma (FL) and large B-cell lymphoma (DLBCL) in individuals exposed to aspirin were 1.12 (95%CI: 0.86-1.45, p=0.37) and 1.03 (95%CI: 0.9-1.19, p=0.6) respectively. Conclusions: In conclusion, individuals taking aspirin do not demonstrate any change in risk of Non-Hodgkins lymphoma.
Keywords
Non-Hodgkins lymphoma; aspirin; meta-analysis; negative influence;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Amanat A, Al-Belushi B, I Waly M, Al-Moundhri M, A Burney Ik (2013). Dietary and lifestyle factors and risk of non-Hodgkin's lymphoma in Oman. Asian Pac J Cancer Prev, 14, 841-8.   DOI   ScienceOn
2 Amoori N, Mirzaei M, Cheraghi M(2014). Incidence of cancers in Kuzestan province of Iran: trend from 2004 to 2008. Asian Pac J Cancer Prev, 15, 8345-9.   DOI
3 Ansell SM, Armitage J (2005). Non-Hodgkin lymphoma: diagnosis and treatment. Proc Mayo Clinic, 80, 1087-97.   DOI
4 Baker JA, Weiss JR, Czuczman MS, et al (2005). Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control, 16, 301-8.   DOI
5 Baecklund E, Iliadou A, Askling J, et al (2006). Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum, 54, 692-701.   DOI
6 Binesh F, Akhavan A, Behniafard N, Atefi A (2014). Clinicopathologic and survival characteristics of childhood and adolescent non Hodgkin's lymphoma in Yazd, Iran. Asian Pac J Cancer Prev, 15, 1585-8.   DOI
7 Boffetta P, de Vocht F (2007). Occupation and the risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 16, 369-72.   DOI
8 Broccia G, Cocco P, Casula P (2001). Incidence of non-Hodgkin's lymphoma and Hodgkin's disease in Sardinia, Italy: 1974-1993. Haematologica, 86, 58-63.
9 Cerhan JR, Anderson KE, Janney CA, et al (2003). Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer, 106, 784-8.   DOI
10 Chang ET, Smedby KE, Hjalgrim H, et al (2005). Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol, 162, 965-74.   DOI
11 Chia SE, Wong KY, Tai BC (2012). Occupation and risk of non-Hodgkin's lymphoma in Singapore. Occup Med, 62, 29-33.   DOI
12 Clarke CA, Glaser SL(2002). Changing incidence of nonhodgkin lymphomas in the United States. Cancer. 94, 2015-23.   DOI   ScienceOn
13 Devesa SS, Fears T (1992). Non-Hodgkin's lymphoma time trends: United States and international data. Cancer research, 52, 5432-40.
14 Erber E, Lim U, Maskarinec G, Kolonel LN(2009). Common immune-related risk factors and incident non-Hodgkin lymphoma: The multiethnic cohort. Int J Cancer, 125, 1440-5.   DOI
15 Ekstrom-Smedby K (2006). Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta Oncol, 45, 258-71.   DOI
16 Flick ED, Chan KA, Bracci PM, Holly EA (2006). Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol, 497, 164-504.
17 Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O (2009). Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica, 94, 647-53.   DOI
18 Hernandez BY, Green MD, Cassel KD, et al (2010). Cancer Research Center Hotline: Preview of Hawai 'i Cancer Facts and Figures 2010. Hawaii Med J, 69, 223.
19 Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI
20 Hoshida Y, Xu J-X, Fujita S, et al (2007). Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medicatio. J Rheumatol, 34, 322-31.n
21 Karami K, Cheraghi M, Amori N, Pedram M, Sobhani A (2014). Common cancers in Khuzestan province, South West of Iran, during 2005-2011. Asian Pac J Cancer Prev, 15, 9475-8.   DOI
22 Kato I, Koenig KL, Shore RE, et al (2002). Use of antiinflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL)(United States). Cancer Causes Control, 13, 965-74.   DOI
23 Rothwell PM, Fowkes FGR, Belch JF, et al (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377, 31-41.   DOI
24 Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al (2012). Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 379, 1602-12.   DOI
25 Sangrajrang S, Renard H, Kuhaprema T, et al (2011). Personal use of hair dyes--increased risk of non-Hodgkin's lymphoma in Thailand. Asian Pac J Cancer Prev, 12, 2393-6.
26 Setoguchi S, Solomon DH, Weinblatt ME, et al (2006). Tumor necrosis factor $\alpha$ antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum, 54, 2757-64.   DOI
27 Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics. CA Cancer J Clin, 61, 212-36.   DOI
28 Teras LR, Gapstur SM, Patel AV, et al (2013). Aspirin and other nonsteroidal anti-inflammatory drugs and risk of non-hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 22, 422-8.   DOI
29 Thun MJ, Jacobs EJ, Patrono C (2012). The role of aspirin in cancer prevention. Nat Rev Clin Oncol, 9, 259-67.   DOI   ScienceOn
30 Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2006). Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev, 30, 99-101.   DOI
31 Zekri AR, Hassan ZK, Bahnassy AA et al (2013). Gene expression profiling of non-Hodgkin lymphomas. Asian Pac J Cancer Prev, 14, 4393-8.   DOI
32 Zelenetz AD, Abramson JS, Advani RH, et al (2010). Non-Hodgkin's lymphomas. J Nat Compr Cancer Netw, 8, 288-334.
33 Yildirim M, Karakilinc H, Yildiz M, et al (2013). Non-Hodgkin lymphoma and pesticide exposure in Turkey. Asian Pacific J Cancer Prev, 14, 3461-3.   DOI   ScienceOn